Skip to main content

Mesh & Graft-Augmented Prolapse Repair

Mesh and graft-augmented vaginal repairs for pelvic organ prolapse (POP) sit at the edge of contemporary pelvic-floor reconstruction: transvaginal synthetic mesh improves anterior-compartment anatomic outcomes, but it adds mesh-specific morbidity; biologic grafts have not shown a meaningful advantage over native-tissue repair; and since April 2019, no FDA-approved transvaginal mesh products remain available in the United States for POP repair.[1][2][3]

This page covers augmented vaginal POP repairs. It should be read separately from sacrocolpopexy, where mesh is placed abdominally, and from midurethral slings for SUI, which were not removed from the US market by the 2019 FDA POP-mesh order.[1][13]

Material Types​

MaterialExamplesCurrent role
Synthetic nonabsorbable meshType I macroporous monofilament polypropyleneMost studied material; improves anterior anatomic cure but adds exposure, pain, bladder injury, de novo SUI, and repeat-surgery risk.[1][3]
Synthetic absorbable meshPolyglactin / Vicryl-type materialsDoes not show durable benefit over native-tissue repair.[3]
Autologous biologic graftRectus fasciaAvoids permanent synthetic material but adds donor-site morbidity and lacks strong POP benefit data.
Allograft / homologous graftCadaveric fascia lataStudied historically; no consistent durable advantage over native repair.[2][3]
Xenograft / alloplastic biologic graftPorcine dermis, porcine small intestinal submucosaNo meaningful benefit over native tissue in contemporary reviews; posterior-compartment outcomes may be worse in some trials.[1][3]

Efficacy by Compartment​

CompartmentSynthetic meshBiologic graftPractical conclusion
AnteriorImproves anatomic cure and reduces bulge recurrence compared with native-tissue repair, but subjective outcomes are often similar.[1][2][4][5]Minimal benefit; similar prolapse awareness and reoperation rates compared with native tissue.[1][3]Anatomic advantage must be weighed against mesh-specific morbidity. In the US, no approved TVM POP product remains available.
PosteriorDoes not improve outcomes.[1][3]Does not improve outcomes and may worsen anatomic results in some trials.[1][3]Do not routinely use mesh or biologic grafts for posterior colporrhaphy.
ApicalNative-tissue vaginal repairs have similar prolapse awareness and reoperation compared with TVM in some analyses, while TVM adds mesh complications.[6] Menefee 2024 found TVM noninferior to sacrocolpopexy for vault prolapse, with sustained patient-reported improvement in all arms.[7]No clear durable role.Sacrocolpopexy is usually the mesh-based durability benchmark; vaginal mesh is a restricted / non-US option for selected recurrent or high-risk cases.

Trial Anchors​

PROSPECT​

The PROSPECT trial randomized 1,348 women undergoing primary transvaginal anterior and / or posterior compartment prolapse surgery. Augmentation with either synthetic mesh or biologic graft did not improve prolapse symptom scores or quality of life at 1 or 2 years compared with standard repair. Mesh complications occurred in 12% of mesh-exposed women within 2 years.[5]

FDA 522 study​

An FDA-mandated 522 study comparing transvaginal mesh with native tissue repair reported 36-month composite success of 89.3% for mesh versus 80.2% for native tissue, demonstrating noninferiority but not superiority on the primary endpoint. Serious adverse events were similar at about 3%.[8]

PROSPERE​

The PROSPERE multicenter trial comparing laparoscopic sacrocolpopexy with transvaginal mesh for primary cystocele showed similar long-term success rates, but grade III or higher complications were more common after TVM (8.7% vs. 2%).[9]

Contemporary apical vault prolapse RCT​

Menefee 2024 randomized women with apical vault prolapse to native-tissue repair, sacrocolpopexy, or transvaginal mesh. Sacrocolpopexy was superior to native-tissue repair, and TVM was noninferior to sacrocolpopexy, though all groups improved patient-reported outcomes.[7]

Mesh-Specific Complications​

For the canonical complications and removal reference — IUGA / ICS classification, complete-vs-partial removal evidence, surgical-approach algorithm, ACOG Committee Opinion 694 management framework — see Mesh Complications & Removal. The summary below is the indication-and-augmentation-context view.

The 2024 Cochrane review of transvaginal mesh, grafts, and native-tissue repair included 51 trials and provides the most useful complication frame.[3]

ComplicationSignal
Vaginal mesh exposure11.8% overall; 6.1% required surgical intervention.[3]
Repeat surgeryTotal repeat surgery for prolapse, SUI, or mesh exposure is higher with mesh.[1]
De novo SUIIncreased after mesh-augmented repair.[3]
Bladder injuryHigher with mesh placement.[3]
Dyspareunia / painPain is a major driver of mesh removal; dyspareunia is reported in about 7% of sexually active patients in contemporary summaries.[3][10]
Erosion range by compartment burdenReported erosion rates range from 1.4-19% after anterior wall placement and 3-36% when mesh spans multiple compartments.[2]

Risk factors for mesh erosion include larger vaginal incision size, sexual activity, higher BMI, and smoking.[11] Mesh complications are not purely technical; the host response to polypropylene is shaped by the vaginal hormonal and microbial environment, implant porosity, surface area, and chronic immune activation.[12]

Regulatory Timeline​

YearAction
2008FDA public health notification after more than 1,000 adverse events over 3 years.[1]
2011FDA safety communication identified serious safety and effectiveness concerns.[1][2]
2016FDA reclassified transvaginal POP mesh as Class III high-risk devices.[1][3]
2017Australia cancelled approval of two TVM products; UK NICE restricted TVM to research; Scotland halted use.[1]
2018FDA ordered posterior-compartment TVM off the market; Australia cancelled all TVM approvals.[1]
2019FDA ordered all remaining transvaginal mesh products for POP off the US market.[3][13]

The FDA order applies to transvaginal mesh for POP. It does not apply to midurethral slings for SUI or to abdominal mesh used in sacrocolpopexy.[1][13]

Guideline Position​

ACOG Practice Bulletin 214 and AUGS guidance support a restricted role for transvaginal mesh and graft augmentation:[1][14]

  • Native-tissue repair is first-line for most primary POP repairs.
  • Transvaginal mesh should be limited to carefully selected high-risk patients in whom benefit may justify risk, such as recurrent anterior / apical prolapse or patients whose comorbidity profile makes abdominal reconstruction undesirable.
  • Surgeons must have specialized training in mesh placement, patient selection, and complication management.
  • Informed consent must include mesh-specific risks and native-tissue / abdominal alternatives.
  • Routine intraoperative cystoscopy is recommended when mesh is placed in the anterior or apical compartments.
  • Synthetic mesh or biologic grafts should not be used routinely for posterior vaginal wall prolapse.

Because no FDA-approved TVM products for POP remain available in the United States, US counseling is usually framed around native-tissue vaginal repair versus abdominal / minimally invasive sacrocolpopexy, not a free choice among native, TVM, and SCP options.

Mesh and Graft Complication Management​

ACOG / AUGS guidance on mesh and graft complications emphasizes symptom-driven management and specialist referral for complex pain, erosion, urinary tract involvement, or failed prior excision.[15]

PresentationManagement frame
Asymptomatic small exposureExpectant management is acceptable for monofilament macroporous mesh.[15]
Small symptomatic exposureTrial topical vaginal estrogen, local care, and observation may be reasonable before excision.[15]
Bleeding, discharge, partner pain, or recurrent exposureOffice trimming may be insufficient; consider operative partial excision with counseling about recurrence and pain persistence.[15][16]
Pain / dyspareunia without visible exposureThe most difficult phenotype; mesh removal may not resolve pain. In one series, complete pain resolution occurred in only about half after operative management.[17]
Urinary tract erosion, fistula, abscess, severe pain, or complex prior excisionRefer to FPMRS / reconstructive specialist; evaluate with cystoscopy, imaging, and multidisciplinary pain care when indicated.[15]

Mesh removal should not be performed without a specific therapeutic indication.[15]

Sacrocolpopexy vs. Transvaginal Mesh​

Sacrocolpopexy uses abdominally placed mesh and generally has a more favorable risk-benefit profile than transvaginal mesh. A systematic review and meta-analysis found lower mesh complication rates, lower de novo dyspareunia, and similar anatomic / subjective success with sacrocolpopexy compared with TVM.[18] The VIGI-MESH registry similarly found fewer serious complications after laparoscopic sacrocolpopexy than TVM at 1 year, with low recurrence reoperation rates.[19]

Long-term data complicate the story: a Finnish nationwide cohort with mean 7.4-year follow-up found similar prolapse reoperation rates across native tissue, transvaginal mesh, and abdominal mesh, with differences in recurrence site rather than a simple winner-takes-all durability pattern.[20]

Long-Term Outcomes​

Mesh complications do not disappear after the early postoperative window. A New York State cohort of 54,194 women found POP repair with mesh associated with higher 5-year reintervention risk than native tissue repair (8.8% vs. 6.3%; HR 1.40).[21] Long-term follow-up cohorts confirm that recurrence, reoperation, and mesh complications remain surveillance issues years after the index procedure.[20]

Future Directions​

Biologic and biomimetic graft materials aim to reproduce the mechanical advantages of synthetic mesh while improving tissue integration and reducing chronic host response. For now, the clinical translation gap remains large: preclinical promise has not yet produced a durable, low-morbidity vaginal graft that clearly outperforms native tissue repair.[22] The 2024 Cochrane review concludes that transvaginal mesh has limited utility in primary surgery and that any ongoing use should occur with ethical oversight and outcomes reported to regulatory bodies.[3]

Cross-references​

References​

1. Pelvic organ prolapse: ACOG Practice Bulletin, Number 214. Obstet Gynecol. 2019;134(5):e126-e142. doi:10.1097/AOG.0000000000003519

2. Schimpf MO, Abed H, Sanses T, et al. Graft and mesh use in transvaginal prolapse repair: a systematic review. Obstet Gynecol. 2016;128(1):81-91. doi:10.1097/AOG.0000000000001451

3. Yeung E, Baessler K, Christmann-Schmid C, et al. Transvaginal mesh or grafts or native tissue repair for vaginal prolapse. Cochrane Database Syst Rev. 2024;3:CD012079. doi:10.1002/14651858.CD012079.pub2

4. Capobianco G, Sechi I, Muresu N, et al. Native tissue repair versus transvaginal mesh interventions for the treatment of anterior vaginal prolapse: systematic review and meta-analysis. Maturitas. 2022;165:104-112. doi:10.1016/j.maturitas.2022.07.013

5. Glazener CM, Breeman S, Elders A, et al. Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery: two parallel-group, multicentre, randomised, controlled trials (PROSPECT). Lancet. 2017;389(10067):381-392. doi:10.1016/S0140-6736(16)31596-3

6. Maher C, Feiner B, Baessler K, et al. Surgery for women with apical vaginal prolapse. Cochrane Database Syst Rev. 2016;10:CD012376. doi:10.1002/14651858.CD012376

7. Menefee SA, Richter HE, Myers D, et al. Apical suspension repair for vaginal vault prolapse: a randomized clinical trial. JAMA Surg. 2024;159(8):845-855. doi:10.1001/jamasurg.2024.1206

8. Kahn B, Varner RE, Murphy M, et al. Transvaginal mesh compared with native tissue repair for pelvic organ prolapse. Obstet Gynecol. 2022;139(6):975-985. doi:10.1097/AOG.0000000000004794

9. Lucot JP, Cosson M, Verdun S, et al. Long-term outcomes of primary cystocele repair by transvaginal mesh surgery versus laparoscopic mesh sacropexy: extended follow up of the PROSPERE multicentre randomised trial. BJOG. 2022;129(1):127-137. doi:10.1111/1471-0528.16847

10. Yang J, Zhang K, Han J, et al. Long-term observation on postoperative recurrence and complications of transvaginal mesh surgery for pelvic organ prolapse. Gynecol Obstet Invest. 2022;87(1):30-37. doi:10.1159/000520979

11. Cetin Arslan H, Arslan K. Risk factors and outcomes of vaginal mesh erosions after pelvic reconstructive surgery: a retrospective cohort study. Medicine (Baltimore). 2025;104(19):e42442. doi:10.1097/MD.0000000000042442

12. Abhari RE, Izett-Kay ML, Morris HL, Cartwright R, Snelling SJB. Host-biomaterial interactions in mesh complications after pelvic floor reconstructive surgery. Nat Rev Urol. 2021;18(12):725-738. doi:10.1038/s41585-021-00511-y

13. Winkelman WD, Modest AM, Richardson ML. U.S. Food and Drug Administration statements about transvaginal mesh and changes in apical prolapse surgery. Obstet Gynecol. 2019;134(4):745-752. doi:10.1097/AOG.0000000000003488

14. Pelvic organ prolapse. Female Pelvic Med Reconstr Surg. 2019;25(6):397-408. doi:10.1097/SPV.0000000000000794

15. American College of Obstetricians and Gynecologists. Management of mesh and graft complications in gynecologic surgery. Updated 2025.

16. Abbott S, Unger CA, Evans JM, et al. Evaluation and management of complications from synthetic mesh after pelvic reconstructive surgery: a multicenter study. Am J Obstet Gynecol. 2014;210(2):163.e1-163.e8. doi:10.1016/j.ajog.2013.10.012

17. Crosby EC, Abernethy M, Berger MB, et al. Symptom resolution after operative management of complications from transvaginal mesh. Obstet Gynecol. 2014;123(1):134-139. doi:10.1097/AOG.0000000000000042

18. Zhang CY, Sun ZJ, Yang J, et al. Sacrocolpopexy compared with transvaginal mesh surgery: a systematic review and meta-analysis. BJOG. 2021;128(1):14-23. doi:10.1111/1471-0528.16324

19. Fritel X, de Tayrac R, de Keizer J, et al. Serious complications and recurrences after pelvic organ prolapse surgery for 2309 women in the VIGI-MESH registry. BJOG. 2022;129(4):656-663. doi:10.1111/1471-0528.16892

20. Wihersaari O, Karjalainen P, Tolppanen AM, et al. Prolapse recurrence, methods of reoperation, and long-term mesh complications: a nationwide follow-up study. Acta Obstet Gynecol Scand. 2025. doi:10.1111/aogs.70083

21. Chughtai B, Mao J, Asfaw TS, et al. Long-term device outcomes of mesh implants in pelvic organ prolapse repairs. Obstet Gynecol. 2020;135(3):591-598. doi:10.1097/AOG.0000000000003689

22. Whooley J, Cunnane EM, Do Amaral R, et al. Stress urinary incontinence and pelvic organ prolapse: biologic graft materials revisited. Tissue Eng Part B Rev. 2020;26(5):475-483. doi:10.1089/ten.TEB.2020.0024